Baird lowered the firm’s price target on Dyne Therapeutics (DYN) to $32 from $46 and keeps an Outperform rating on the shares. The firm updated its model following the swapping of the DYNE-101 endpoint from splicing to vHOT.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics: Strategic Advancements and Promising Clinical Data Drive Buy Rating
- Dyne Therapeutics’ DYNE-101 Gains Momentum with FDA Breakthrough Designation and Optimized Clinical Trials
- Dyne having vHOT as primary endpoint ‘encouraging,’ says H.C. Wainwright
- Positive Outlook for Dyne Therapeutics: Buy Rating Justified by Promising DYNE-101 Trial Results and Strategic Moves
- Dyne at ‘attractive entry point’ following pullback, says Chardan